PMID: 11318796Apr 25, 2001Paper

Haemophilias: advances towards genetic engineering replacement therapy

Clinical and Laboratory Haematology
G EmilienC Casimir

Abstract

Both haemophilia A and B are X-linked recessive disorders and therefore occur almost exclusively in males. The genes for both factors VIII and IX have been mapped to the distal end of the long arm of the X chromosome, bands Xq28 and Xq27.1, respectively. The Factor VIII gene comprises 186 kb DNA with 9 kb of exon of DNA which encodes an mRNA of nearly 9 kb. The Factor IX gene is 34 kb in length and the essential genetic information is present in eight exons which encode 1.6 kb mRNA. In gene therapy, genetic modification of the target cells can be either ex vivo or in vivo. The advantage of the ex vivo approach is that the genetic modification is strictly limited to the isolated cells. In the in vivo approach, the integrity of the target tissue is maintained but the major challenge is to deliver the gene to the target tissue. The use of improved retroviral and adenovirus-based vectors for gene therapy has produced clinically relevant levels of human factor VIII in mice and haemophilic dogs. If further improvements can increase the persistence of expression and decrease the immunological responses, phase I clinical trials in patients can be considered.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y DaiI M Verma
Feb 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T D PalmerA D Miller
Jan 1, 1991·Human Gene Therapy·K CornettaW F Anderson
Jun 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·R ScharfmannI M Verma
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·R M KotinK I Berns
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J H AxelrodI M Verma
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D ArmentanoS L Woo
Jan 19, 1989·The New England Journal of Medicine·G C WhiteC B Shoemaker
May 1, 1989·Southern Medical Journal·W S RobertsG H Lyman
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·D St Louis, I M Verma
Nov 1, 1987·Archives of Internal Medicine·W B White, L H Baker
Jan 1, 1995·Pathology·N S Van de WaterP J Browett
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·V J DwarkiL K Cohen
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·J F EngelhardtJ M Wilson
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y YangJ M Wilson
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·K ZatloukalM L Birnstiel
Feb 1, 1993·Nature Genetics·A J GerrardF M Watt
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·J WalterK A High
Jan 20, 1996·Human Gene Therapy·S ConnellyM Kaleko
Aug 10, 1997·Human Gene Therapy·J N LozierR A Morgan
Nov 5, 1997·Current Opinion in Nephrology and Hypertension·E Imai
Dec 5, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A KayP M Hoogerbrugge
Oct 17, 1998·Current Opinion in Hematology·R W Herzog, K A High
Nov 6, 1998·Pharmacology & Therapeutics·P D Robbins, S C Ghivizzani
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·S Connelly, M Kaleko
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·M A Kay
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·K P Gioia, J D Bouhasin
Jan 12, 1999·Nature Medicine·R M Linden, S L Woo

❮ Previous
Next ❯

Citations

Oct 5, 2006·Current Opinion in Anaesthesiology·Sunitha GovindaswamyAlain Vuylsteke

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Current Opinion in Hematology
F J Fallaux, Rob C Hoeben
Clinical Chemistry and Laboratory Medicine : CCLM
Giuseppe CastaldoFrancesco Salvatore
Bulletin et mémoires de l'Académie royale de médecine de Belgique
M K L Chuah, T Vandendriessche
© 2021 Meta ULC. All rights reserved